Iovance Biotherapeutics (IOVA) Income Annual - Discounting Cash Flows
Iovance Biotherapeutics, Inc.
IOVA (NASDAQ)

* (except for per share items) of USD
Period Ending: LTM
(Last Twelve Months)
2024
12-31
2023
12-31
2022
12-31
2021
12-31
2020
12-31
2019
12-31
2018
12-31
2017
12-31
2016
12-31
2015
12-31
2014
12-31
2013
12-31
2012
12-31
2011
12-31
2010
12-31
2009
12-31
2008
12-31
Report Filing 2025-02-27 2024-02-28 2023-02-28 2022-02-24 2021-02-25 2020-02-25 2019-02-28 2018-03-12 2017-03-09 2016-03-11 2015-03-16 2014-03-28 2013-09-23 2012-03-30 2011-04-14 2010-03-31 2009-02-17
Revenue
164 1.19 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Cost of Revenue
124 10.8 21.1 14.0 8.71 8.12 0.96 0.95 0.98 1.00 9.34 4.66 6.48 19.3 0.00 0.00 0.00
Gross Profit
40.1 -9.57 -21.1 -14.0 -8.71 -8.12 -0.96 -0.95 -0.98 -1.00 -9.34 -4.66 -6.48 -19.3 0.00 0.00 0.00
Operating Expenses
435 451 378 329 253 199 127 91.9 52.7 26.9 2.70 18.0 1.66 1.92 0.82 0.02 0.06
Research & Development
282 344 295 259 202 166 99.8 71.6 28.0 15.5 2.70 1.33 1.66 1.76 0.00 0.00 0.00
Selling, General and Administrative
153 107 104 83.7 60.2 40.8 28.4 21.3 25.6 12.4 9.34 4.66 6.48 19.3 0.00 0.01 0.03
Other Operating Expenses
0.00 0.00 -21.1 -14.0 -8.71 -8.12 -0.96 -0.95 -0.98 -1.00 -9.34 12.0 -6.48 -19.1 0.82 0.00 0.03
Operating Income
-395 -461 -399 -343 -262 -207 -128 -92.9 -53.6 -27.9 -12.0 -22.6 -8.13 -21.2 -0.82 -0.02 -0.06
Net Non-Operating Interest
20.3 13.0 0.00 0.45 2.36 9.32 0.00 0.81 0.74 0.00 -0.01 -0.44 -2.42 -0.15 0.00 0.00 0.00
Interest Income
20.3 13.0 2.98 0.45 2.36 9.32 0.00 0.81 0.74 0.20 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Interest Expense
0.00 0.00 2.98 0.00 0.00 0.00 0.00 0.00 0.00 0.20 0.01 0.44 2.42 0.15 0.00 0.00 0.00
Equity & Other Income/(Expense)
0.00 0.00 2.98 0.00 0.00 0.00 4.68 0.00 0.00 0.20 0.01 -2.30 7.24 -4.32 -0.79 0.00 0.00
Income Before Tax
-375 -448 -396 -342 -260 -198 -124 -92.1 -52.9 -27.7 -12.0 -25.4 -3.31 -25.7 -1.61 -0.02 -0.06
Income Tax Expense
-2.83 -3.48 -5.97 -14.4 -2.36 -10.5 4.68 -0.95 -0.98 -1.00 0.00 0.44 2.42 4.64 0.79 0.00 0.00
Income Attributable to Non-Controlling Interest
0.00 0.00 0.00 0.00 0.00 0.00 -4.68 0.95 0.98 1.00 0.00 -0.44 -2.42 -4.64 -0.79 0.00 0.00
Net Income
-372 -444 -390 -328 -257 -187 -124 -92.1 -52.9 -27.7 -12.0 -25.4 -3.31 -25.7 -1.61 -0.02 -0.06
Depreciation and Amortization
0.00 33.1 21.1 14.0 8.71 8.12 0.96 0.95 0.98 1.00 0.09 0.01 0.01 0.00 0.06 0.00 0.00
EBITDA
-395 -427 -378 -329 -253 -199 -127 -91.9 -52.7 -26.9 -12.0 -22.6 -8.13 -21.2 -0.76 -0.01 -0.06
Earnings Per Share (EPS)
-1.280 -1.890 -2.450 -2.140 -1.860 -1.500 -1.270 -1.410 -0.960 -0.620 -0.480 -2.600 -4.140 -33.84 -2.460 -0.041 -0.047
Diluted Earnings Per Share
-1.280 -1.890 -2.450 -2.140 -1.860 -1.500 -1.270 -1.410 -0.960 -0.620 -0.480 -2.600 -4.140 -33.84 -2.460 -0.041 -0.047
Weighted Average Shares Outstanding
290 235 159 153 138 124 97.3 65.2 55.3 44.4 25.0 9.76 0.80 0.76 0.65 0.38 1.21
Diluted Weighted Average Shares Outstanding
290 235 159 153 138 124 97.3 65.2 55.3 44.4 25.0 9.76 0.80 0.76 0.65 0.38 1.21
discounting cash flows home logo

Discounting Cash Flows

Are you finding our services helpful? Review us on trustpilot logo Trustpilot
Have a question? Contact us